Additionally, we found that CD226+ T cells were enriched with NK‐T‐like cells, with prominent cytotoxic capabilities [83], and have been linked to a better clinical outcome in CLL [84, 85], multiple myeloma [86], and colorectal cancer [87]. This evidence concerns the gene CD226 and plasma cell myeloma.